Nootropics Index - Save on smarter supplements
Isolated phytochemicals & plant compounds

Yohimbine

Yohimbine

Yohimbine is an alpha-2 adrenergic antagonist best understood as a high-caution stimulant-like alkaloid, not a general nootropic. Human evidence is strongest in narrow erectile-function and pharmacology contexts, while cognitive and performance claims remain limited or mixed.

WakefulnessPhysical PerformanceLibido VitalityAdrenergicIsolated CompoundBioavailability SensitiveClinical Research
Updated June 2026/5 min read/13 citations
Prepared by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Related form

Yohimbine is the isolated alkaloid found in Yohimbe Bark Extract.

Isolated from
Botanical source / extractYohimbe Bark ExtractBotanical & herbal supplements
View

Yohimbine is the isolated alkaloid. Yohimbe bark extract is the botanical source and can vary by alkaloid content, standardization, and labeling accuracy.

01

What is it?

Overview

3

Yohimbine is an indole alkaloid from yohimbe bark and a pharmacologically active alpha-2 adrenergic antagonist. It is better framed as a high-caution adrenergic compound than as a broad nootropic: the human evidence is concentrated in erectile-function and pharmacology studies, while cognitive-performance claims remain weak.

Not a general nootropic8
Yohimbine can feel stimulating because it increases adrenergic signaling, but stimulation is not the same as reliable focus, memory, or learning support. Safety and product-quality cautions are more important than nootropic positioning.
02

Names, aliases and forms

Salt FormYohimbine HCl
Common NameYohimbe
Cas Number146-48-5
Active ConstituentYohimbine
03

Mechanisms of action

Mechanism snapshot

8

Yohimbine blocks alpha-2 adrenergic receptors, including presynaptic autoreceptors that normally restrain norepinephrine release. That mechanism can increase noradrenergic tone, which helps explain both activating effects and adverse effects such as anxiety, palpitations, and blood-pressure sensitivity.

04

Potential effects and evidence map

Yohimbine has human pharmacology data and modest clinical evidence in erectile-function studies of purified yohimbine HCl, but the evidence does not establish broad cognitive benefit. Small performance/body-composition studies are limited, and safety/product-quality literature supports a high-caution profile for supplement use.

Effect domainMagnitudeGrade
Mental energy / wakefulness8
AcuteConfidence: Medium

may feel activating through adrenergic stimulation, but this is not the same as demonstrated cognitive-performance benefit

Note Human pharmacology supports noradrenergic activation; no broad nootropic benefit is established.

1/5
C
Libido / vitality4
Acute + cumulativeConfidence: Medium

has modest human evidence in erectile-function studies of purified yohimbine HCl, with limited relevance to OTC yohimbe bark supplements

Note This profile describes evidence context only and does not recommend use for a medical condition.

2/5
B
Physical energy / endurance10
AcuteConfidence: Low

has limited human performance evidence; a small soccer-player trial did not improve measured exercise-performance outcomes

Note Body-composition findings from small athlete studies should not be generalized to broad fat-loss or performance claims.

1/5
C
05

Typical dosages and timing

Typical
5-10 mg
Not a recommendation
Lower bound
5 mg
Profile value
Upper bound
10 mg
Profile value
Studied dose25-10 mg

Clinical references for purified yohimbine HCl commonly discuss low milligram doses, but supplement labels can be inaccurate and yohimbe bark products are not interchangeable with standardized yohimbine HCl. Treat this as study context, not a recommendation.

06

Onset, duration and tolerance

Onset<1 hour
Duration1-2 hours
Half-life0.6 hours
Peak9<1 hour
Absorption and variability9

Human pharmacokinetic studies report rapid absorption and elimination, but oral bioavailability varies widely between individuals, which can make dose-response and tolerability unpredictable.

07

Safety, side effects and risk profile

High caution6
Yohimbine-containing products have been associated with gastrointestinal distress, tachycardia, anxiety or agitation, hypertension, and more severe outcomes in poison-center reports. This is a poor fit for people sensitive to stimulants or cardiovascular activation.
Cardiovascular caution6
Confidence: High

Tachycardia, hypertension, chest symptoms, and more severe outcomes have been reported with yohimbine-containing products.

Note Poison-center data and FDA safety communications support a high cardiovascular-caution rating.

4/5
B
Overstimulation / insomnia7
Confidence: High

Anxiety, agitation, tremor, palpitations, and insomnia-like stimulation are plausible and clinically documented concerns.

Note Yohimbine increased anxiety and somatic symptoms in human noradrenergic challenge research, especially in panic-prone patients.

4/5
B
Interaction risk13
Confidence: High

Stimulants, MAOIs, some antidepressants, ADHD medications, and blood-pressure-active drugs raise interaction concerns.

Note FDA and NCCIH materials flag greater risk with stimulant and psychiatric-medication combinations.

4/5
B
Pregnancy / lactation caution1
Confidence: High

Pregnancy and lactation safety is not established, and the adrenergic risk profile makes conservative avoidance appropriate.

Note Added as a precaution because safety data are insufficient and adverse cardiovascular/neurologic effects are plausible.

4/5
E
Legal / regulatory risk1
Confidence: High

Regulatory treatment differs by product type and jurisdiction; OTC products cannot be marketed as ED treatments in the U.S. without FDA approval.

Note EFSA and NCCIH/FDA sources support public wording that separates legal/regulatory context from clinical claims.

3/5
C
Evidence uncertainty5
Confidence: High

Yohimbe bark supplements vary in composition, and clinical yohimbine HCl evidence should not be generalized to every supplement product.

Note Label-content mismatch and EFSA safety uncertainty justify a persistent evidence/product-quality uncertainty warning.

3/5
C
08

Interactions and cautions

Interaction cautions13

Potentially risky combinations include stimulant-heavy products, caffeine or ephedra-style stimulants, ADHD stimulants, MAOIs, certain antidepressants, and blood-pressure-active medications. FDA safety notices also flag greater risk in people taking stimulants, ADHD medications, MAOIs, or some antidepressants.

10

How it compares

Not interchangeable5

Most clinical evidence concerns purified yohimbine HCl, while yohimbe bark extracts can vary in alkaloid content and may contain related alkaloids. Product analyses found large differences between labeled and measured yohimbine content.

11

Practical buying and quality notes

  • Avoid treating generic yohimbe bark blends as equivalent to quantified yohimbine HCl. The safest quality screen is a product that clearly states yohimbine amount, avoids stimulant stacking, and provides independent testing for identity and dose accuracy.5
12

FAQ

Is yohimbine a nootropic?

3

Not in the usual evidence-based sense. It has adrenergic stimulant-like pharmacology, but human evidence does not establish reliable focus, memory, or learning benefits.

Is yohimbe bark the same as yohimbine HCl?

5

No. Yohimbine HCl is the purified salt form used in much of the clinical literature. Yohimbe bark supplements can vary substantially in alkaloid content and labeling accuracy.

Who should avoid yohimbine?

1

People with cardiovascular disease, uncontrolled hypertension, anxiety or panic disorders, stimulant sensitivity, pregnancy or lactation, or use of stimulants, ADHD medications, MAOIs, certain antidepressants, or blood-pressure-active medications should avoid yohimbine unless a qualified clinician specifically advises otherwise.

13

References

  1. National Center for Complementary and Integrative Health. Yohimbe: Usefulness and Safety. Last updated May 2025.
  2. National Institute of Diabetes and Digestive and Kidney Diseases. Yohimbine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury.
  3. Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacology & Therapeutics. 2001;91(3):215-243.
  4. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. Journal of Urology. 1998;159(2):433-436.
  5. Cohen PA, Wang YH, Maller G, DeSouza R, Khan IA. Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Testing and Analysis. 2016;8(3-4):357-369.
  6. Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Annals of Pharmacotherapy. 2010;44(6):1022-1029.
  7. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety: effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Archives of General Psychiatry. 1984;41(8):751-763.
  8. Hedner T, Edgar B, Edvinsson L, Hedner J, Persson B. Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. European Journal of Clinical Pharmacology. 1992;43(6):651-656.
  9. Guthrie SK, Hariharan M, Grunhaus LJ. Yohimbine bioavailability in humans. European Journal of Clinical Pharmacology. 1990;39(4):409-411.
  10. Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Research in Sports Medicine. 2006;14(4):289-299.
  11. Cimolai N, Cimolai T. Yohimbine use for physical enhancement and its potential toxicity. Journal of Dietary Supplements. 2011;8(4):346-354.
  12. EFSA Panel on Food Additives and Nutrient Sources Added to Food. Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe). EFSA Journal. 2013;11(7):3302.
  13. U.S. Food and Drug Administration. Branch Manager for Men may be harmful due to hidden drug ingredient. Medication Health Fraud Notification. Content current as of June 10, 2026.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.